

- Particulate matter  
 and lung neoplasm development  
 74:44, 45  
 pollution levels in four U.S. locations  
 75:65, 66
- Particulate phase, cigarette smoke  
 64:51-60, 263, 264, 265  
 carcinogenic accelerators in  
 72:5, 65  
 effect on pulmonary and cardiac structure and function  
 72:7-8  
 harmful constituents in  
 72:143
- Particulate phase, tobacco smoke  
 composition of  
 64:51  
 deposition sites of  
 64:264, 265  
 gravitational settling of  
 64:264  
 measurement of  
 64:263  
 removal of  
 64:264  
 respiratory damage from  
 64:279  
 retention of  
 64:264, 300  
 water content of  
 64:51
- Passive smokers  
 pathologic studies  
 75:99  
 summary of previous findings  
 75:87, 88  
 summary of recent findings  
 75:107, 108
- Passive smoking  
 CO, nicotine, benzo(a)pyrene, acrolein and acetaldehyde levels  
 75:90-95  
 effect on cardiovascular function in dogs  
 73:14  
 effect on children  
 72:129  
 effect on respiratory tract in laboratory animals  
 72:129, 130  
 effects of carboxyhemoglobin levels, in persons with angina pectoris  
 75:95, 97  
 effects of carboxyhemoglobin levels on CO absorption  
 75:95, 96  
 effects of CO in tobacco smoke on psychomotor performance  
 75:99-101  
 effects of exposure to cigarette smoke, in passive smokers  
 75:99  
 effects of tobacco smoke constituents  
 75:88-98  
 effects on bus and plane passengers  
 75:102  
 excretion of nicotine  
 75:97  
 exposure to cigarette smoke, and development of eye and throat irritations  
 75:99, 100  
 incidence of pneumonia and bronchitis in children of parental smokers  
 75:105, 106  
 maternal smoking, and development of bronchitis and pneumonia in infants  
 75:103, 104  
 in neoplasm induction in laboratory animals  
 72:130  
 parental cough and phlegm production, and respiratory symptoms in children  
 75:103
- Pathophysiological studies  
 alveolar macrophages and smoking  
 75:76, 77  
 effects of cigarette smoke on leukocytes, in guinea pigs  
 75:77, 78  
 effects of cigarette smoke on pulmonary macrophages, in guinea pigs  
 75:77, 78  
 effects of smoking on tracheal mucus velocity, in dogs  
 75:78  
 suppression of immunoglobulin response by nicotine or water soluble fraction of cigarette  
 75:77
- Patulin  
 64:145
- Peak Flow Meter  
 64:290
- Pearl's hypothesis  
 64:105
- Peer group status  
 64:372, 373
- Penicillic acid  
 64:145
- Penis  
 skin neoplasms of  
 64:147
- Pentacyclic compounds  
 64:54
- Pentolinium  
 blockage of nicotine cardiac stimulation by  
 71:57
- Peoples Gas Company Study  
 epidemiologic study of smoking and CHD  
 74:6, 7
- Peoples Gas Light and Coke Co.  
 study of CHD, serum cholesterol and smoking relationships  
 71:43
- Peptic ulcer  
 64:337-340  
 antacid efficacy and healing of, effects of cigarette smoking on  
 71:423  
 cessation of smoking as therapy for  
 67:182  
 cigarette smoking in  
 64:39

- clinical studies
  - 73:155-157
- development in smokers
  - 71:13
- and diet
  - 67:182
- duodenal, and smoking
  - 67:39
- epidemiological studies
  - 73:155-157
- gastric, morbidity, and smoking
  - 67:40, 182
- gastric, mortality, and smoking
  - 67:40, 181-182
- gastric secretion in smokers vs. nonsmokers
  - 73:157, 158
- incidence rates, smokers vs. nonsmokers, by sex
  - 67:182
- increased mortality in Japanese smokers vs. nonsmokers
  - 73:155, 156
- increased prevalence in male smokers
  - 72:97
- and lung neoplasms, relation to smoking
  - 69:57
- morbidity, and smoking
  - 67:40, 181
- mortality rates
  - 67:40; 71:423
- mortality rates, by amount smoked
  - 67:182
- mortality rates, by smoking classification
  - 67:182
- mortality rates, smokers vs. ex-smokers
  - 67:181
- mortality ratios, for men by age
  - 67:181
- mortality ratios from
  - 64:339, 340
- mortality ratios from, in smokers and nonsmokers
  - 71:424
- mortality ratios from, smokers vs. ex-smokers by age
  - 67:181
- mortality ratios in Japanese adults by age started smoking
  - 73:155, 156
- mortality ratios in male cigar and pipe smokers
  - 73:222
- predisposing factors
  - 73:157
- recurrence in smokers vs. nonsmokers
  - 73:157
- retrospective and cross section study methods for smoking relationship to
  - 71:425-427
- smoking and
  - 67:22, 39-40, 181-182; 72:5, 6, 97, 98; 73:155
- smoking as cause in dogs
  - 72:26
- Perception
  - of health hazards, and smoking behavior
    - 67:191
- 1,8,9-Perinaphthoxanthene
  - 64:54
- Perinatal studies
  - effect of maternal smoking on me
    - summary of findings
      - 73:134, 135
    - maternal smoking and
      - 72:83-88
- Periodontal diseases
  - smoking and
    - 69:85-86; 72:6
  - smoking and, in Ceylon
    - 69:85-86
  - smoking and, in Norwegian Ar
    - cruits
      - 69:85
- Peristalsis
  - 64:71
- Peroxides
  - suspected carcinogenic agent in c
    - smoke
      - 71:265
- Personality characteristics
  - 64:365-368
  - and coronary disease
    - 64:321; 67:57
  - coronary disease morbidity ratios
    - ers vs. nonsmokers by
      - 67:57
  - drug use and
    - 64:353
  - relationship to CHD and smoking
    - 71:48-49, 105-106
  - in smokers
    - 64:326, 365-368
  - and smoking habit
    - 67:57, 188-192
  - and smoking habit in college stuc
    - 67:189
- Pesticides
  - 64:61, 62, 145
  - content in cigarette smoke
    - 71:265, 266
- pH
  - pipe/cigar smoke inhalation and
    - 73:183
  - of smoke in cigarettes, cigars, a
    - cigars
      - 73:223, 224, 228
- Phagocytosis
  - 64:35, 267, 269, 270, 300
  - effect of cigarette smoke in lab
    - animals
      - 73:53, 54
  - effect of cigarette smoke in rabbi
    - 72:109
  - effect of tobacco smoke
    - 72:47-48
  - pulmonary alveolar, in smokers
    - smokers
      - 71:165
- Pharyngeal fungi
  - smokers vs. nonsmokers in Sout
    - 73:54
- Pharyngeal neoplasms
  - 64:201, 202
  - frequency in smokers vs. nonsmo
    - 71:238

- incidence of secondary primary, smokers vs. nonsmokers 75:50
- mortality rates, by smoking classification 67:35, 146-147
- mortality rates, cigar smokers vs. nonsmokers 67:146
- mortality rates, for men by amount smoked 67:147
- mortality rates, for women 67:153
- mortality rates, pipe smokers vs. nonsmokers 67:146
- mortality ratios 67:35
- mortality ratios, by smoking classification 67:146
- mortality ratios, for cigar smokers 67:35
- mortality ratios, for cigar smokers by age 67:146
- mortality ratios, for men by age 67:146
- mortality ratios, for men by amount smoked 67:146-147
- mortality ratios, for pipe smokers 67:35
- mortality ratios, for pipe smokers by age 67:146
- recurrent, incidence in smokers vs. ex-smokers 73:74, 75
- relationship to tobacco use 71:362-364, 366
- retrospective studies of, by type of smoking 64:200, 201
- smoking in etiology of 67:35, 145, 147
- Phenols
  - 64:49, 54, 58, 59, 61, 62, 145, 267
  - in cigar, pipe, and cigarette smoke 73:177
  - ciliatotoxic agents 67:108
  - cocarcinogens 67:131
  - as probable contributors to health hazards of smoking 72:144
  - suspected carcinogenic agent of cigarette smoke 71:266
  - in tobacco smoke 67:129
  - tumor promoting agents 67:129
- Phenotypes
  - partially deficient heterozygote, in COPD etiology 75:73, 74
- Phenylmethyloxadiazole (PMO)
  - protection against adverse effects of cigarette smoke in animals 73:49, 53
- Philadelphia Pulmonary Neoplasm Research Project
  - lung neoplasm histopathologic studies and 74:38
- Phlebitis 64:103
- Phlegm production
  - by occupation and smoking habit 67:97
  - by parental smokers, and development of respiratory symptoms in children 75:103
  - by parental smokers, and incidence of pneumonia and bronchitis in children 75:105, 106
  - by smoking habit and sex 67:98
- Phospholipids
  - function as surfactants in lung tissue 71:172
  - smokers vs. nonsmokers 71:99-100, 102
- Physical activity 64:322
  - as a factor in coronary heart disease 73:4, 5
  - myocardial infarct morbidity ratios, for smokers vs. nonsmokers by level of 67:56
  - occupational, and smoking habit 67:56
  - relationship to myocardial infarction, smokers vs. nonsmokers 71:44
  - and risk of cerebrovascular accident 67:68
  - smoking and, relationship to CHD 71:41, 43, 44
- Physique smokers 64:383-387
- Phytadiene 64:51
- Phytol
  - structural formula of 64:52
- Picoline 64:59
- Pigmentation
  - induction of 64:146
- Pigments 64:272
  - in lungs of emphysematous patients 64:273
- Pinocytosis
  - decrease in alveolar macrophages, in smokers vs. nonsmokers 75:76
  - effect of nicotine, in mouse peritoneal macrophages 74:105

- Piperidine, nitroso-  
suspected carcinogenic properties in cigarette smoke from  
71:265
- Pipe smoke  
see Smoke, pipe
- Pipe smokers  
see Smokers, cigar and pipe; Smokers, pipe
- Pipe smoking  
see Smoking, pipe
- Pipe tobacco  
see Tobacco, pipe
- Pitch  
64:147, 229  
skin neoplasms from  
64:33
- Placebos  
ginseng root as  
64:355  
nicotine-free cigarettes as  
64:70
- Placenta  
ability to hydroxylate benzo(a)pyrene in smoking mothers  
71:407  
morphology  
64:343
- Platelets  
see Blood platelets
- Plethysmogram  
abnormalities, in smokers vs. nonsmokers  
73:22
- Pleural neoplasms  
mesotheliomas, classification of  
64:174
- Plumbers  
neoplasm risks in  
64:134
- Pneumoconiosis  
64:269, 290, 298  
in coal miners  
72:42-44  
in coal miners, smokers vs. nonsmokers  
73:42  
smokers vs. nonsmokers  
72:42-44
- Pneumonia  
64:277, 294, 302  
epithelial changes in  
64:170  
incidence in children of smokers  
75:105, 106  
maternal smoking, and development in infants  
75:103  
mortality ratios in  
64:276  
neoplastic-like pathology in  
64:195  
in passive smokers, summary of recent findings  
75:108  
phenol induction of  
64:267
- Pneumothorax, spontaneous  
smoking and  
73:37
- Poisson distribution  
in mortality rates  
64:117, 118, 119
- Poland  
bladder neoplasms, in, methods and results in retrospective studies of smoking and  
71:382, 383  
CHD mortality and morbidity in,  
71:96  
esophageal neoplasms in Polish-born  
64:135  
esophageal neoplasms in, retrospective studies of tobacco use with  
64:214; 71:378  
gastric neoplasms in Polish-born  
64:135  
laryngeal neoplasms in, retrospective studies of tobacco use with  
64:205, 208; 71:357  
lung neoplasms, in males  
64:135  
oral neoplasms in, retrospective studies of tobacco use with  
64:200, 201; 71:364  
serum lipid differences in smoker nonsmokers in  
71:100, 102  
smoking and nicotine effects on human blood levels in  
71:124  
smoking relationship to thrombosis  
71:131
- Polonium 210  
64:145  
carcinogenicity  
67:128  
in cigarette smoke  
67:128  
levels in lung tissue, smokers vs. smokers  
67:128  
and lung neoplasms  
67:128  
suspected carcinogenic agent in cigarette smoke  
71:265-267, 335-336  
in tobacco leaf  
67:128  
as tumor initiator  
67:128
- Polyoma virus  
64:166
- Polyphenols  
64:54
- Population studies  
British physicians, mortality and smoking (Doll and Hill Study)  
67:5, 17, 52, 93, 139, 155, 18  
bronchitis and smoking  
69:37  
Canadian pensioners smoking and study  
67:5, 48, 93, 138, 154, 159  
U.S. population, mortality and smoking (Hammond)  
67:5, 13, 49-54, 66, 69, 94, 13  
146-158, 181-189

- U.S. veterans, mortality and smoking (Dorn)
  - 67:5, 13, 48-49, 67-69, 92, 137-139, 146-159, 181-184
- Portland student study
  - 64:368
- Postal employees
  - breathlessness in
    - 64:286
  - chronic cough in
    - 64:281
- Post-operative complications
  - in duodenal ulcer removal, smokers vs. nonsmokers
    - 73:157
  - incidence in bronchitic and nonbronchitic smokers vs. nonsmokers
    - 74:92
  - pulmonary, smokers vs. nonsmokers
    - 71:174-175; 72:38
  - smoking, obesity, anesthesia and
    - 73:39
- Potassium
  - 64:55
- Potassium-40
  - 64:145
  - present in tobacco leaf
    - 71:266
- Preeclampsia
  - maternal smoking and
    - 69:79; 72:84; 73:142
  - in smoking vs. nonsmoking women
    - 71:404, 407; 73:142
- Pregnancy
  - carboxyhemoglobin levels in fetuses
    - 75:26, 27
  - carboxyhemoglobin levels of smokers in
    - 69:80
  - effect of blood pressure and smoking habits on
    - 69:77-78
  - effect of nicotine on, in rats
    - 69:80
  - effect of smoking during
    - 64:343; 67:185-187; 69:4-5, 77-81; 71:4, 13, 82-87, 389, 397-399, 415; 73:103-142
  - effect of smoking during, and development of bronchitis and pneumonia in infants
    - 75:103, 104
  - effect of smoking during, in Hungary
    - 69:79
  - effect of smoking during, in Ireland
    - 69:79
  - effect of smoking during, in Scotland
    - 69:79
  - effect of smoking during, in Venezuela
    - 69:79
  - effect of tobacco smoke, nicotine, and carbon monoxide in laboratory animals
    - 73:114-118
  - effects of nicotine on uterus during
    - 67:187
  - human, methods used in smoking study of
    - 71:391-396
  - nicotine effects on myometrial strips in
    - 71:408
  - and previous smoking habits, effect on infant birth weight
    - 73:112-114
  - summary of previous findings
    - 75:5, 6
  - timing of influence of smoking on birth weight
    - 73:120, 121
  - unsuccessful, smoking effects on
    - 71:13
  - see also* Maternal fetal exchange; Smoking, maternal
- Premalignant lesions
  - in bronchi
    - 64:27
  - in epithelial tissue
    - 64:231
  - in oral cavity
    - 64:142
- Prematurity
  - and maternal smoking
    - 64:343; 67:185-186; 69:77, 79; 71:390, 400-403; 72:5, 83-87; 73:112
  - and maternal smoking, among Negroes
    - 69:78
- Presbyterian Hospital Study
  - 64:141, 174
- Pressure-volume work loops
  - 64:292
- Prevalence studies
  - 64:301
  - in bronchopulmonary disease
    - 64:280-293
  - pulmonary function tests in
    - 64:280
  - sputum production in
    - 64:383
- Printing ink
  - 64:193
- Professional workers
  - smoking incidence of
    - 64:187
- Promoting agents
  - 64:26, 142, 146, 229
  - ethyl alcohol as
    - 64:217
  - urethan as
    - 64:142
- Propane
  - 64:60
- beta-Propiolactone
  - 64:145
- Propionaldehyde
  - 64:52
- Propionic acid
  - ciliatotoxic agent
    - 67:108
  - in tobacco smoke
    - 67:108
- Propylene
  - 64:60
- Prospective mortality studies
  - age adjustments in
    - 64:84

- alcohol in
  - 64:99, 101
- by American Cancer Society
  - 64:81, 96, 101
- by Best, Josie, and Walker
  - 64:81
- British doctors study* as
  - 64:97, 102, 109
- California occupational study as
  - 64:95, 106
- Canadian study as
  - 64:91, 92, 94
- cause of death in
  - 64:109
- certification validity in
  - 64:109, 110
- city population size in
  - 64:99
- comparison of
  - 64:83
- by Dorn
  - 64:81
- by Dunn, Buell, and Breslow
  - 64:81
- by Dunn, Linden, and Breslow
  - 64:81
- educational level in
  - 64:100, 101
- exercise in
  - 64:101
- in ex-smokers
  - 64:93
- fried foods in
  - 64:100
- genetic longevity in
  - 64:99
- by Hammond
  - 64:81
- by Hammond and Horn
  - 64:81
- infectious diseases in
  - 64:276
- inhalation practices in
  - 64:99
- limitations in
  - 64:94, 95, 96, 111, 163
- male death rates in
  - 64:28
- maternal smoking in
  - 64:343
- mortality ratios in
  - 64:84, 118
- nonresponse bias in
  - 64:96, 97, 104
- occupational exposure in
  - 64:100, 101
- previous disease in
  - 64:100, 101
- religious factors in
  - 64:99, 101
- smoking data in
  - 64:82
- socioeconomic factors in
  - 64:96
- tranquilizers in
  - 64:100
- twenty five-state study as
  - 64:103, 104
- type of smokers in
  - 64:82
- usable responses in
  - 64:96
- U.S. veterans study as
  - 64:91, 94, 96, 97, 103
- variables affecting
  - 64:84
- weaknesses of
  - 64:96
- Prospective studies
  - 64:27, 28, 30, 81-116, 293, 29323
- bias in
  - 64:36
- by Doll and Hill
  - 64:81
- esophageal neoplasms
  - 64:217
- excess deaths in
  - 64:28
- in gastric neoplasms
  - 64:227
- methodology of
  - 64:81
- methodology of, in peptic ulcer
  - 64:338, 339
- morphology correlations in
  - 64:385, 386
- neoplasms
  - 64:231
- neoplasms by site
  - 64:149
- reliability of
  - 64:180
- Prostatic neoplasms
  - 64:135, 136
- mortality rates in
  - 64:131
- mortality ratios in
  - 64:148, 149
- Protestants
  - smoking prevalence in
    - 64:364
- Protozoa
  - ciliary function in, effect of
    - smoke on
      - 71:165, 224
- Pseudoephedrine
  - 64:349
- Psychoanalytic theory
  - 64:367
- Psychomotor performance
  - effects of CO in tobacco smoke
    - 75:99-101
  - in passive smokers, summary of
    - findings
      - 75:108
- Psychosocial factors
  - in cardiovascular disease
    - 64:327
  - smoking habit
    - 67:39, 188-192
- Psychosomatic disorders
  - in heavy smokers
    - 64:367
- Psychotherapy
  - cure of tobacco habit by
    - 64:354

- Public Health Service
  - 64:6, 13, 127, 34<sup>2</sup>
  - 1967 study of, starting point for new studies
    - 71:4
  - review of medical literature on smoking hazards
    - 71:7
- Public transportation
  - effects of passive smoking on bus and plane passengers
    - 75:102
- Puerto Rico
  - esophageal neoplasms in, retrospective studies of tobacco use with
    - 71:378
  - relationship of tobacco use and neoplasms of oral cavity in
    - 71:367
- Puffmeter ratios
  - 64:291, 292
- Pulmonary alveoli
  - changes in rates after exposure to nitrogen dioxide
    - 69:41
  - effect of smoking on
    - 64:274, 275; 67:30, 107
  - epithelium
    - 64:165
  - epithelium, experimentally induced changes in
    - 64:272
  - fluid lining, smoking effects on
    - 64:269, 270
  - rupture, in pipe/cigar smokers vs. cigarette smokers and nonsmokers
    - 73:217
  - septa, rupture of
    - 64:35, 274, 275, 301
  - septa, thickening of
    - 64:275
  - stability, cigarette smoke in
    - 64:35, 300
- Pulmonary clearance
  - effect of heavy smoking
    - 73:52, 53
  - effect of nitrogen dioxide, in rats
    - 74:103
  - effect of smoking
    - 72:3, 47; 73:55; 74:101, 102
  - effect of sulfur dioxide on
    - 64:295
  - mechanical vs. bactericidal clearance in guinea pigs
    - 73:53
  - mechanism, in smokers vs. nonsmokers
    - 73:52, 53
  - in monozygotic vs. dizygotic twins
    - 73:51
  - particle deposition in smokers vs. nonsmokers
    - 73:53
  - in smokers, ex-smokers, and nonsmokers with and without pulmonary disease
    - 74:100, 101
  - see also* Pulmonary function
- Pulmonary diseases
  - see* Lung diseases
- Pulmonary edema
  - nitrogen dioxide in
    - 64:266
- Pulmonary embolism
  - 64:103
- Pulmonary emphysema
  - see* Emphysema
- Pulmonary fibrosis
  - 64:35, 301
  - in asbestos textile workers
    - 72:44
  - autopsy studies, smokers vs. nonsmokers
    - 75:74-76
  - chronic
    - 64:277-294
  - in heavy smokers
    - 64:274
  - in moderate smokers
    - 64:274
  - obliterating
    - 64:266
  - in pipe/cigar smokers vs. cigarette smokers and nonsmokers
    - 73:217
  - smokers vs. nonsmokers
    - 71:161
  - smoking and
    - 67:107; 72:44
- Pulmonary function
  - 64:35
  - abnormalities, and rheumatoid arthritis in smokers vs. nonsmokers
    - 74:92, 93
  - abnormalities, during viral illness, in smokers vs. nonsmokers
    - 75:63
  - in asymptomatic young men in Romania
    - 73:39
  - before and after smoking one non-filter cigarette
    - 74:99
  - of Boston policemen, smokers vs. nonsmokers
    - 74:82, 83
  - closing volume abnormalities as indicator of small airways disease
    - 75:71, 72
  - in coal miners, smokers vs. nonsmokers
    - 73:42, 43
  - in coal miners vs. nonminers
    - 73:42
  - decline in forced expiratory volume, in smokers by race
    - 75:72
  - diffusing capacity, smokers vs. nonsmokers in Berlin, New Hampshire
    - 73:50, 51
  - effect of asbestos exposure and smoking
    - 73:41
  - effect of cigarette smoke, in monkeys
    - 74:102
  - effect of coal dust exposure and smoking
    - 73:41-43
  - effect of dust exposure and smoking
    - 74:95
  - effect of exercise performance and smoking
    - 74:99

- effect of isoproterenol in smokers, non-smokers and bronchitics  
74:99, 100
- effect of lung hyperinflation in coal miners  
73:42, 43
- effect of nitrogen dioxide, in animals  
74:102, 103
- effect of smoking  
69:5, 42; 72:37, 38; 74:80
- effect on exercise performance in smokers vs. nonsmokers  
73:246, 247
- in ex-smokers  
73:39
- of insurance company employees, smokers vs. nonsmokers  
74:80, 81
- in jet fighter pilots, smokers vs. nonsmokers  
73:43
- of male and female smokers, in New Guinea  
74:81, 82
- of male executives, smokers vs. nonsmokers  
74:81
- in males from industrial town in England, smokers vs. nonsmokers  
68:69
- of pipe and cigarette smokers, ex-smokers, and nonsmokers  
74:99
- in pipe/cigar smokers vs. nonsmokers  
73:217, 221
- prevalence of deficient heterozygote phenotypes, in smokers vs. nonsmokers  
75:74
- pulmonary hypertension and  
73:43
- respiratory flow resistance  
64:266
- small airways disease, smoking, and  
74:84-87; 75:71, 72
- in smokers vs. nonsmokers  
67:99-101; 72:40; 73:55; 74:80-82
- in smokers vs. nonsmokers in Berlin, New Hampshire  
73:50, 51
- in smokers vs. nonsmokers, under 30 years of age  
73:50
- smoking and  
73:38, 39
- summary of recent findings  
75:78
- tests  
64:278, 292
- volume tests  
64:292
- in young smokers  
67:110-111
- see also* Pulmonary clearance; Respiratory function tests
- Pulmonary heart disease  
COPD and  
72:24
- smoking as cause  
72:24, 27
- Pulmonary surfactant  
effect of smoke  
67:110; 72:48
- effect of smoking  
69:42; 73:55
- Pyelitis  
64:224
- Pyrene  
64:59, 147
- in cigar, pipe, and cigarette smoke  
73:178
- Pyridine  
64:54, 59
- as suspected contributor to health hazards of smoking  
72:145
- 3-Pyridylacetic acid  
64:72
- gamma- (3-Pyridyl)-gamma-methyl butyric acid  
64:71, 72
- gamma- (3-Pyridyl)-gamma-oxo-butyric acid  
64:72
- Pyrolysis  
64:50, 53, 59, 62
- Pyrrolidine, nitroso-suspected carcinogenic properties  
rette smoke from  
71:265
- Pyruvic acid  
64:53
- Quassia  
64:354
- Quinine  
64:354
- Quinoline  
64:54
- Rabbits  
atherogenic effects of carbon monoxide and hypoxia  
71:64
- atherogenic effects of nicotine  
71:120-122
- blood lipids in, smoking and effects on  
71:127
- cardiovascular function in, smoking  
nicotine effects  
71:108, 109
- cholesterol fed, carbon monoxide on  
71:65-66
- ciliary function in, cigarette smoke  
effect on  
71:221-222
- ciliastasis in  
64:268
- coronary blood flow in  
64:318



- leukoplakia in
  - 64:233
- neoplasm induction in
  - 64:143, 146, 202, 203
- offspring, nicotine and smoke effects on
  - birth weight
    - 71:407
  - offspring, smoking effects on stillbirth and mortality
    - 71:411
- pregnant, tritium-labeled nicotine effects in
  - 71:413
- pulmonary changes in cigarette smoking
  - 71:159
- pulmonary clearance in, cigarette smoke effect on
  - 71:164, 170, 171
- pulmonary damage in
  - 64:266
- skin painting, smoke condensate effects on
  - 71:267, 338
- smoke deposition in
  - 64:265
- Race
  - 64:224, 363, 364
  - as a factor in coronary heart disease
    - 73:4, 5, 23
  - as a factor in perinatal mortality in smoking vs. nonsmoking mothers
    - 73:129-132
  - as a factor in stillbirth rates
    - 73:124, 125
- Radiation exposure
  - smoking and, as cause of respiratory cancers
    - 73:72
  - smoking and, in uranium miners
    - 72:64, 65
- Radioactive carbon
  - 64:166
- Radioactive cerium
  - 64:166
- Radioactive particles
  - in tobacco leaf, tobacco smoke, and smokers' lungs
    - 73:72
- Radioactive substances
  - epidermoid neoplasms from
    - 64:166, 230
  - as tracers
    - 64:265
- Radioactivity
  - 64:145, 166, 193, 230
- Radionuclides
  - 64:193
- Radium
  - 64:145
- Radon
  - inhalation
    - 64:145
- Rats
  - alveolar lining changes in
    - 64:269, 270
  - atherosclerosis in, nicotine induced
    - 64:319; 71:120, 121
  - blood lipids in, nicotine and smoke effects
    - 71:128
  - carcinoma induction in
    - 64:165
  - ciliary function in, cigarette smoke on
    - 71:221, 222
  - clearance mechanisms in
    - 64:269
  - epidermoid lung neoplasm induction in
    - 64:66
  - hepatoma induction in
    - 64:145
  - LD<sub>50</sub> nicotine determination in female
    - 71:412
  - lung neoplasms, from intrabronchial implanting of chromium compounds
    - 71:258
  - lung neoplasms, from nickel carbonyl and dust inhalation
    - 71:256
  - lungs, cigarette smoke effects on surfactant activity
    - 71:172, 225
  - mucous cell increase in
    - 64:269
  - neoplasm induction in
    - 64:143
  - offspring, nicotine and smoke effects on birth weight
    - 71:407
  - pregnant, aromatic compound stimulation of placental BP-hydroxylase activity
    - 71:414
  - pregnant, fetal wastage and neonatal death in nicotine and smoking
    - 71:411
  - pulmonary carcinoma induction following asbestos dust inhalation
    - 71:257
  - pulmonary changes from chronic nitrogen dioxide inhalation
    - 71:161, 220
  - pulmonary damage in
    - 64:269
  - respiratory tract, cigarette smoke inhalation effects
    - 71:268, 349, 353
  - sarcoma induction in
    - 64:266
  - skin painting, smoke condensates effect
    - 71:267, 340
  - tobacco allergy in
    - 64:319
  - trachea, cigarette smoke effects on
    - 71:343
  - tracheal ligation, cigarette smoke and papain effects on
    - 71:163
  - tracheobronchial tree, cigarette smoke effects on
    - 71:268, 346-349
- Reading ability
  - in children of smoking mothers
    - 71:407
- Rectal neoplasms
  - 64:103

- Registrar General of England and Wales  
64:134
- Relative risk ratios
  - amount smoked in  
64:161
  - Cornfield method in  
64:160
  - measure of  
64:183
- Religion  
64:244
  - cure of tobacco habit  
64:354
  - in prospective studies  
64:99, 101
  - and smoking habit  
67:54, 97
  - smoking prevalence by  
64:364
- Reserpine
  - nicotine cardiac stimulation blockage by  
71:57
- Residues  
64:145
- Resorcinol  
64:54
- Respiration
  - effect of nicotine, clinical and experi-  
mental studies  
67:26
  - rate  
64:266
- Respiratory function tests  
64:289-293, 297
  - body height effect on  
64:290
  - effect of smoking  
72:45
  - in ex-smokers  
67:100
  - smokers  
71:146-147, 206-214
  - smokers vs. nonsmokers by sex  
67:99
  - smokers vs. nonsmokers, twins  
67:103
  - of smokers with mild bronchitis  
69:39
  - by smoking history  
67:100
  - using radioactive xenon  
69:39
  - and young smokers  
67:100-101
  - see also Pulmonary function; Respira-  
tory system
- Respiratory symptoms  
68:69, 70, 71
  - effect of air pollution and smoking  
74:90, 91
  - effect of air pollution exposure levels in  
telephone workers  
75:67
  - effect of asbestos exposure in smokers  
vs. nonsmokers  
73:41
  - effect of cigarette smoke  
68:73, 74
- pipe/cigar smokers and cigarette smo  
vs. nonsmokers  
72:3, 40
- prevalence in cement and rubber in  
try workers, smokers vs. nonsmo  
74:95, 96
- prevalence in children of parental sn  
ers  
75:102, 103
- prevalence in Duisburg, Germany, by  
and cigarette consumption  
73:39
- prevalence in ex-smokers  
73:39
- prevalence in pipe and cigar smokers  
73:217, 220, 221
- prevalence in smokers vs. nonsmoker:  
73:55
- prevalence in smokers vs. nonsmoker:  
Bordeaux, France  
73:36
- in school children  
67:69, 70, 71
- in smokers vs. nonsmokers  
68:66, 67, 71; 75:62, 63
- in smokers vs. nonsmokers by amo  
smoked  
73:37
- summary of previous findings  
75:5
- summary of previous findings on i  
tiation to passive smoking  
75:88
- summary of recent findings  
75:78
- in women  
64:286
- Respiratory system
  - acute effect of cigarette smoke on  
man pulmonary function  
71:163, 166-169
  - animal, cigarette smoke instillation  
implantation effects on  
71:268, 346-348
  - animal, effect of cigarette smoke inh  
tion on  
71:268-269, 349-353
  - defense mechanisms in  
64:267, 268
  - effect of cigarette and cigar smoke  
bronchial reactivity  
71:164
  - effect of cigarette smoke on hun  
ciliary function  
71:165, 221-224
  - effect of cigarette smoke on hun  
pulmonary clearance  
71:164, 170
  - effect of smoking on  
67:141
  - glossary of terms used in testing  
71:215
  - histological changes in smokers  
64:270-274; 71:154-157
  - improvements in function follow  
smoking cessation  
71:148, 149

- irritation, prevalence in rubber industry workers, smokers vs. nonsmokers 74:96
- pathological changes in cigarette smokers 71:175
- postoperative complication in, of smokers vs. nonsmokers 71:174-176, 230
- pulmonary alveolar phagocytosis in smokers vs. nonsmokers 71:165
- pulmonary infarction in dogs inhaling cigarette smoke 71:271
- surface tension of, effect of cigarette smoke on 71:172, 225
- surfactant activity of, in smokers vs. nonsmokers 71:172, 225
- surfactants in, definition 71:172
- see also* Bronchi; Lungs
- Respiratory tract diseases 64:263-302
  - by amount smoked 67:97
  - chronic, definition 64:288
  - chronic, epidemiology 64:297, 298
  - cigarette smoking and 64:276
  - clinical evidence of 64:294
  - definition of 64:289
  - epidemiology of 64:297, 298
  - etiology of 64:302
  - infections, in emphysema development 67:111
  - infections, prevalence in smokers 71:10, 176
  - infections, smoking and 67:29; 71:172, 226-229; 72:3, 38
  - non-influenzal, in smokers vs. nonsmokers 72:48
  - pathological and cytological changes in, of smokers vs. nonsmokers 71:258-263
  - role of constitutional factors in 67:102-104
  - role of heredity factors in 67:102-104
  - rural vs. urban dwellers 67:97
  - smokers vs. nonsmokers, by age 67:100
  - smokers vs. nonsmokers, by occupation 67:97
  - by smoking characteristics 67:97-98
  - by smoking classification 67:97-98
  - in smoking-discordant twin pairs 67:102-104
  - twin studies 67:102-104
  - ventilatory function in, smokers vs. nonsmokers 71:175
  - see also* Lung diseases
- Respiratory tract neoplasms
  - carcinogenesis induction in animals 74:46, 47
  - by country, in females 64:131
  - experimental induction of 69:63-64
  - mortality rates 67:147
  - mortality trends in 64:136
  - and smoking 67:10
  - and smoking classification 67:147
  - see also* Lung neoplasms
- Respondents
  - age-adjusted death rates in 64:114
  - mortality ratios in 64:116
- Restricted activity days
  - by age, sex, and smoking history 67:19-21
  - definition of 67:19
- Reticulosarcoma
  - and cigarette smoke 67:148
  - and tobacco tars 67:148
- Retinal sensitivity
  - to tobacco 64:341
- Retinoblastoma 64:191
- Retrospective studies 64:27, 28-31, 150-157, 160, 161, 198, 199
  - association of diseases in 64:160, 161
  - control groups in 64:181
  - definition of 64:27
  - inhalation patterns in 64:159
  - laryngeal neoplasms 64:233, 234
  - lung neoplasms, and smoking, methods 71:323-328
  - lung neoplasms, duration of smoking in 64:158
  - maternal smoking 64:343
  - methods 64:152, 153, 154, 198, 199, 200
  - mortality studies 64:150

- peptic ulcer
  - 64:337
- reliability of
  - 64:180
- risk ratios in
  - 64:160, 161
- smoking characteristics in
  - 64:156
- Reverse smoking
  - 64:203, 204
  - effect on oral mucosa
    - 72:6, 69, 70
  - heat effects in
    - 64:204
  - leukoplakia and
    - 73:76
  - nicotine stomatitis and
    - 72:6, 69, 70
  - oral neoplasms and
    - 73:76
- Rhesus monkeys
  - 64:166
- Rheumatic heart disease
  - mortality from
    - 64:103, 325
- Rhinitis
  - 64:275
- Rhodesia
  - methods used in retrospective studies of
    - smoking in relation to lung neo-
      - plasms
        - 71:328
- Risk factors
  - in coronary heart disease
    - 72:16-18
- Risk ratios
  - calculation of
    - 64:183, 230
  - on cessation of smoking, in lung neo-
    - plasms
      - 64:187, 188
  - consistency of
    - 64:182, 183
  - by lifetime cigarette consumption
    - 64:161
  - in lung neoplasms
    - 64:187, 188
- RNA
  - binding of polycyclic hydrocarbons to
    - 73:86, 87
  - synthesis, effect of cigarette smoke on
    - 69:62, 63
- Rodents
  - carcinogenesis tests in
    - 64:142
  - ozone effect on
    - 64:142
- Roswell Park Memorial Institute
  - 64:174, 219
- Rubber
  - carcinogenic activity of
    - 64:147
- Rubidium-84
  - tracing capillary flow in coronary blood
    - flow
      - 71:59
- Rum
  - 64:62
- Running
  - effect of smoking
    - 73:243, 244
- Rural areas
  - 64:99
  - lung neoplasm incidence in, in Switzer-
    - land
      - 71:244
  - relationships of lung neoplasm to smok-
    - ing, air pollution, and
      - 71:252-255
  - smokers in
    - 64:99, 364
- Rural populations
  - lung neoplasms in, suspected etiology of
    - increased
      - 71:276
- Rural vs. urban populations
  - bladder neoplasm prevalence
    - 64:225
  - mortality rates
    - 67:11
  - smoking and
    - 67:97
- Russia
  - atherogenic effects of nicotine on rabbits
    - in
      - 71:120
  - atherosclerosis autopsy studies in
    - 71:54
  - cigarette tar effects on rat tracheo-
    - bronchial tree in
      - 71:348
  - gastric neoplasms, in Russian-born
    - 64:135
  - gastric neoplasms in Russian Jews
    - 64:135
- Rutin
  - structural formula of
    - 64:54
- Saliva
  - 64:203
  - interference in action of carcinogens on
    - oral cavity
      - 71:288
- Salivary gland neoplasms
  - 64:134
  - see also Mouth neoplasms; Oral neo-
    - plasms
- Salivary glands
  - 64:271
- Sample selection
  - bias resulting from
    - 64:180, 181
- Sarcomas
  - anaplastic, tar induction of
    - 64:223
  - classification of
    - 64:174
  - formation following animal skin painting
    - with smoke condensates
      - 71:338, 340
  - induction in rats by cigarette smoke
    - injection
      - 71:346-347

- induction of
    - 64:144, 176
  - subcutaneous
    - 64:143
- Saslow Psychosomatic Screening Inventory
  - 64:367
- Saturated fats
  - 64:322
- Scholastic achievement
  - 64:370, 372
- School children
  - smoking and respiratory systems in
    - 68:69, 70, 71
- School grade level
  - smoking prevalence by
    - 64:361, 362
- Scotland
  - respiratory symptoms in miners of
    - 64:288, 298
- Scotoma
  - 64:341
- Scottish Home and Health Department
  - Standing Medical Advisory Committee
    - 64:304
- Scrotal neoplasms
  - 64:147
- Secondary infections
  - 64:272
- Sedation
  - smoking effect as
    - 64:350
- Sedatives
  - withdrawal treatment with
    - 64:352
- Selection bias
  - in health studies
    - 64:180, 181
- Selenium
  - carcinogenicity
    - 67:128
  - in cigarette smoke
    - 67:128
  - potential respiratory carcinogenesis
    - 68:92
- Senile keratosis
  - 64:203
- Sensory drives
  - 64:354
- Seven Countries Study
  - epidemiologic study of smoking and
    - CHD
      - 74:6
- Seventh Day Adventists
  - coronary disease incidence in
    - 64:322
  - laryngeal neoplasm prevalence in
    - 64:209
  - lung neoplasm prevalence in
    - 64:155
- Sex
  - acute diseases in smokers and non-
    - smokers by
      - 67:22
    - ages of cigarette smokers by
      - 71:6
    - bed days by, and smoking history
      - 67:20-21
    - bladder neoplasm mortality rates in
      - United States by
        - 67:154
    - bronchitis, prevalence rates by
      - 67:96
    - cerebrovascular disease mortality rates,
      - by age and
        - 67:66
    - cerebrovascular disease mortality rates,
      - by smoking classification and
        - 67:66
    - cerebrovascular disease mortality ratios,
      - by age and
        - 67:66
    - cerebrovascular disease mortality ratios,
      - by smoking classification and
        - 67:66
    - chronic diseases in smokers and non-
      - smokers by
        - 67:22
    - coronary disease incidence rates and
      - smoking history by
        - 69:21-22, 24
    - coronary disease mortality rates, by
      - 67:25, 47, 50, 56; 69:13, 17
    - coronary disease mortality ratios, by
      - 67:49; 69:13
    - cough and smoking habit by
      - 67:98
    - effect of, in alpha-1-antitrypsin defi-
      - ciency emphysema
        - 71:151
    - effect of, in lung neoplasms and tobacco
      - use
        - 71:244, 329-333
    - effect of, in mortality in cigarette smok-
      - ers
        - 71:276
    - effect of, on laryngeal neoplasm inci-
      - dence development
        - 71:277
    - emphysema mortality rates
      - 67:91
    - esophageal neoplasm mortality rates
      - 67:150
    - laryngeal neoplasm mortality rates
      - 67:148
    - liver cirrhosis mortality rates, by
      - 67:184
    - liver cirrhosis mortality ratios, by
      - 67:184
    - lung neoplasm development by
      - 71:11
    - lung neoplasm mortality rates by
      - 67:34, 134, 140; 71:252
    - lung neoplasm mortality ratios by
      - 67:33, 134, 140
    - mortality by, and smoking history
      - 67:23
    - mortality rates of cigarette smokers by
      - 71:3
    - pancreatic neoplasm mortality rates, by
      - 67:158
    - pancreatic neoplasm mortality ratios, by
      - 67:158
    - peptic ulcer morbidity rates, by
      - 67:182

- ratio, effect of maternal smoking on  
73:135, 136
- ratio, in lung neoplasm mortality  
74:40, 46
- ratio, in lung neoplasm mortality in  
Norway and Finland  
71:245-246
- restricted activity days by, and smoking  
history  
67:20-21
- and smoking habit  
67:4
- stroke mortality rates by  
69:13, 17
- stroke mortality ratios by  
69:13
- tumor prevalence among smokers by  
69:56
- Sex differentials  
64:133
- in lung cancer  
64:185, 186
- in smoking prevalence  
64:363
- Sheep  
pregnant, nicotine injection and smoke  
inhalation effects on  
71:414
- Sheet metal workers  
neoplasm risks in  
64:134
- Sheldon somatotyping method  
64:383
- Shoe repairers  
bladder neoplasms in  
64:222, 224
- Side stream smoke  
see Smoke streams
- Silica  
64:271
- Silver nitrate  
64:354
- Single-breath tests  
smokers vs. nonsmokers  
73:51
- Sinusitis  
64:275
- in smokers and nonsmokers  
67:22
- Sitosterols  
64:52
- Skin  
benzo(a)pyrene effect on  
64:146
- effect of tobacco extracts  
72:105-107
- reactions of, tobacco induced  
64:319
- tests of  
64:143
- tobacco antigens and  
72:7, 104, 105
- Skin neoplasms  
64:143, 144
- carcinogenic induction of  
64:229
- carcinoma in situ  
64:172
- experimentally induced by ci  
smoke  
67:144
- mineral oil induction of  
64:229
- ultraviolet radiation induction of  
64:144
- Skin testing  
for reactions to tobacco  
72:105-107
- Smog  
64:295
- Smoke, cigar  
benzo(a)pyrene content of  
64:58
- chemical constituents in  
73:177-179
- ciliotoxicity  
73:218
- effect of curing methods  
73:218, 219
- effect of pH on inhalation of  
73:183
- little, pH, compared to cigaret  
cigar smoke  
73:224, 228
- tumorigenic activity in laborato  
mals  
73:210-214
- see also Smoke, tobacco
- Smoke, cigarette  
64:50-62
- alteration of coronary blood flow  
71:58
- aromatic hydrocarbons in  
67:127-128
- benzo(a)pyrene content of  
64:58
- and bronchoconstriction in anima  
68:72
- bronchogenic carcinoma induc  
dogs inhaling  
71:269, 270
- butylmethylnitrosamine in  
67:128
- cadmium levels in  
71:154
- carbon monoxide levels in  
71:59
- carcinogenic content of  
75:48
- carcinogenicity  
67:15, 34, 144; 72:65, 66
- carcinogenicity of components  
mals  
71:12, 277
- cause of death in dogs from inhal  
71:271
- chemical constituents in, comp  
pipe/cigar smoke  
73:177, 178
- ciliary activity  
67:107-108, 140; 68:71, 72
- ciliary depression by  
64:61, 265, 267, 268, 270
- ciliary inhibition  
71:267

ciliotoxic effect, mechanism of action  
 67:107  
 cocarcinogenic effect on respiratory tract in rabbits  
 72:67  
 cocarcinogens in  
 64:144  
 composition of  
 64:50-60  
 and decrease in pulmonary macrophages, in guinea pigs  
 75:77, 78  
 deposition patterns of  
 64:265  
 effect of curing methods  
 73:218, 219  
 effect of nickel on induction of lung aryl hydroxylase  
 71:256-257  
 effect on adenosine triphosphatase  
 67:108  
 effect on alveolar macrophages  
 69:42  
 effect on apexcardiogram  
 72:21  
 effect on bacterial retention in hamsters  
 73:54  
 effect on breathing in guinea pigs  
 72:46  
 effect on bronchial epithelium  
 67:107, 144-145  
 effect on bronchial epithelium in dogs  
 69:40; 73:49  
 effect on bronchial mucosa  
 67:30, 104-107, 144-145  
 effect on DNA and RNA synthesis  
 69:62-63  
 effect on *Dunaliella bioculata*  
 69:42  
 effect on influenza virus in mice  
 68:70, 71  
 effect on lung AHH-activity  
 74:50, 51  
 effect on lungs  
 67:106  
 effect on lung surface tension in dogs  
 72:48  
 effect on nasociliary mucosa in donkeys  
 72:47  
 effect on oxidative enzymes  
 67:108  
 effect on phagocytosis in laboratory animals  
 73:53, 54  
 effect on phagocytosis in rabbits  
 72:109  
 effect on pulmonary clearance  
 73:51-53  
 effect on pulmonary macrophage function, in rabbits  
 74:104  
 effect on pulmonary physiology, in animals  
 74:102  
 effect on pulmonary surfactant  
 67:110; 69:42  
 effect on rat and mouse fetus, site of action  
 73:121  
 effect on respiratory tract, in rats  
 74:104  
 effect on tissue cultures  
 69:42; 71:267, 343-345  
 effect on tracheobronchial clearance, in donkeys  
 75:78  
 effect on vascular resistance  
 67:61  
 effect on ventricular fibrillation threshold in dogs  
 73:13, 14  
 endrin in  
 64:62  
 epidermoid neoplasms from  
 64:144  
 experimental induction of bronchial neoplasms  
 67:144-145  
 experimental induction of lung neoplasms by  
 67:144-145  
 experimental induction of tracheal neoplasms by  
 67:144-145  
 experimental studies in dogs  
 73:13, 14  
 experimental studies in laboratory animals  
 72:21  
 exposure magnitude to  
 64:296, 297, 298  
 extract, effect on pulmonary macrophages, in sheep lungs  
 74:105  
 formaldehyde gas in  
 64:266  
 gaseous deposition of  
 64:265  
 harmful constituents of  
 72:8, 141-146  
 heterocyclic nitrogen compounds in  
 67:127  
 high tar, risks in  
 71:11  
 inhalation by dogs, lung neoplasm development  
 71:268-269, 272-274  
 inhalation effects on animal respiratory tract  
 71:268-269, 349, 353  
 inhalation effects on hamster larynx  
 71:281, 284  
 inhalation methods  
 69:62  
 inhalation of, and coronary disease  
 67:54  
 inhalation of, effect on blood pressure  
 67:54  
 and leukemia  
 67:148  
 listing of identified or suspected tumorigenic agents  
 71:264-267  
 and lymphosarcoma  
 67:148  
 metallic constituents of  
 64:55

- naphthylamine content, and bladder carcinogenesis
  - 68:105
- 2-naphthylamine identified in
  - 71:265
- negative ions in
  - 64:268
- neoplastic changes in animals inhaling
  - 71:238-239
- nickel carbonyl in
  - 69:62
- nickel in
  - 64:167
- nicotine content in
  - 67:34
- nitrosamines in
  - 67:127-128
- nonvolatile condensates of
  - 64:50
- phenols in
  - 64:54, 267; 67:127-128
- polonium-210 in
  - 67:128
- positive ions in
  - 64:268
- pyrolysis reactions in
  - 64:50
- radioactivity of
  - 64:145
- reduction of adverse effects in animals by phenylmethyloxadiazole (PMO)
  - 73:49, 53
- and reticulosarcoma
  - 67:148
- selenium in
  - 67:128
- skin neoplasm induction by
  - 67:144
- and sulphur dioxide, effect on glands in laboratory animals
  - 73:49
- suppression of immunoglobulin response, in cell cultures
  - 75:77
- TDE content of
  - 64:62
- tobacco amblyopia relationship to cyanide metabolism in
  - 71:435-436
- see also* Smoke, tobacco
- Smoke condensates
  - see* Tars, cigarettes; Tars, tobacco
- Smoke, pipe
  - benzo(a)pyrene in
    - 64:58
  - carcinogenicity
    - 67:147-148
  - chemical constituents in
    - 73:177, 178
  - ciliotoxicity of
    - 73:218
  - effect of pH on inhalation of
    - 73:183
  - mouth neoplasms experimentally induced by
    - 67:147-148
- tumorigenic activity in laboratory animals
  - 73:210-214
- see also* Smoke, tobacco
- Smokers
  - airway resistance in
    - 64:292, 293
  - alcohol consumption by
    - 64:385
  - allergic reactions in
    - 64:319
  - angina pectoris in
    - 64:325
  - arteriosclerosis in
    - 69:26
  - behavioral variables in
    - 64:112
  - bladder neoplasms in
    - 64:131, 132, 219, 222, 223, 224, 225
  - body weight of
    - 64:326, 384, 385
  - breathlessness in
    - 64:27, 286, 287
  - bronchitis prevalence in
    - 64:289
  - cholesterol levels in
    - 64:326, 385
  - chronic cough in
    - 64:27, 280, 281, 282, 283, 299, 302
  - ciliary effects in
    - 64:27, 34, 35, 61, 168, 169, 170, 172, 173, 267
  - constitutional differences in
    - 64:112, 326
  - coronary disease in
    - 64:322-325
  - current, mortality rates in
    - 64:95
  - current, mortality ratios in
    - 64:93
  - current, neoplasm risk in
    - 64:158
  - current, pulmonary fibrosis in
    - 64:274
  - epithelial changes in
    - 64:165, 167-173, 189, 263-275
  - forced expiratory flow rate in
    - 64:290, 291
  - heavy, risk ratios in
    - 64:161, 213, 232
  - heavy, urban-rural mortality in
    - 64:186, 194
  - hemoglobin levels in
    - 64:319
  - hereditary factors in
    - 64:385
  - I.Q. measurements in
    - 64:370
  - laryngeal neoplasms in
    - 64:131, 132, 133, 209, 211
  - lung function in
    - 64:27
  - lung neoplasms in
    - 64:118, 131, 132, 133, 149-196, 232
  - morphologic constitution of
    - 64:383-387



mortality rates in, from gastric neoplasms  
   64:132  
 mortality rates in  
   64:99, 117, 118, 162, 209, 322, 323  
 mortality rates in, from laryngeal neoplasms  
   64:211  
 nonrespondents among  
   64:114  
 occupational asbestos exposure and carcinogenesis  
   67:35  
 occupational uranium exposure and carcinogenesis  
   67:35  
 oral neoplasms in  
   64:131, 132, 133, 202, 204  
 as percentage of population  
   64:114  
 personality  
   64:39, 326, 365, 368  
 physical characteristics of  
   64:326  
 population of  
   64:45  
 psychological factors in  
   64:112  
 reduction of life expectancy  
   69:3  
 respiratory conditions in  
   64:289  
 risk ratios in  
   64:160, 161, 222, 223, 232  
 risk ratios in, in bladder neoplasms  
   64:222  
 risk ratios in, in lung neoplasms  
   64:161  
 serum cholesterol in  
   64:326  
 smoking patterns in  
   64:177, 178, 179  
 somatotype classification of  
   64:383, 385  
 sputum analysis of  
   69:39-40, 57-58  
 sputum production in  
   64:27, 283-286  
 urban-rural differences in  
   64:99, 101  
 U.S. incidence of  
   64:178, 179  
*see also* Passive smokers; Smokers, cigar; Smokers, cigar and pipe; Smokers, cigarette; Smokers, pipe  
 Smokers, cigar  
   amblyopia in  
     64:341, 342  
   atypical nuclei in male esophageal epithelium  
     71:379  
   bladder neoplasm mortality in  
     64:219, 222, 223, 224, 235  
   bladder neoplasms in  
     71:293-294  
   body weight of  
     64:384  
   carboxyhemoglobin levels in  
     72:21-23  
   cell rows and atypical cells in vocal cords of  
     71:280, 359-360  
   coal miners as  
     64:299  
   COPD morbidity in  
     71:146, 197-198, 201-202, 204-205  
   coronary deaths in  
     64:323  
   decreased neoplasm risk in  
     64:37  
   duodenal ulcers in  
     64:37  
   duration of smoking in  
     64:36  
   effects of smoke on bronchial reactivity  
     71:164  
   epithelial lesions in  
     64:170, 173, 189  
   esophageal neoplasm mortality ratios in  
     71:290  
   esophageal neoplasms in  
     64:213, 217, 218, 234  
   fibrosis in  
     64:291  
   forced expiratory volume in  
     64:291  
   gastric ulcers in  
     64:37  
   gingival neoplasms in  
     64:202  
   inhalation practices in  
     64:36, 92, 188  
   kidney neoplasms in  
     71:294-295  
   lack of risk in CVD  
     71:67  
   laryngeal neoplasm induction in  
     71:12, 354-357  
   laryngeal neoplasms in  
     64:37, 192, 205, 209, 211, 212;  
     71:281  
   lip neoplasms in  
     64:197, 202, 230, 240  
   lung neoplasms in  
     64:37, 150, 155, 159, 163, 170, 173, 175, 188, 1  
   lung neoplasms, incidence in rural Switzerland  
     71:244  
   lung neoplasms, mortality in  
     71:11, 240-243  
   morphological constitution of  
     64:385, 386  
   mortality rates in  
     64:30, 36  
   mortality ratios from COPD in  
     71:142-143, 145  
   mortality ratios from pancreatic neoplasms in  
     71:298  
   mortality ratios from peptic ulcer in  
     71:424  
   mortality ratios in  
     64:86, 87, 107, 112, 163  
   myocardial arteriole wall thickness in  
     72:19  
   myocardial infarction in  
     71:32, 38-39

- oral neoplasms in
  - 64:37, 189, 192, 202
- pharyngeal neoplasms in
  - 64:202
- relationship of neoplasms of oral cavity with
  - 71:12, 361-365, 367-371
- relationship to infectious respiratory diseases
  - 71:227
- relative risk in esophageal neoplasm development
  - 72:68
- relative risk in laryngeal neoplasm development
  - 72:67
- relative risk in lung neoplasms development
  - 71:276; 73:67, 68
- respiratory diseases in
  - 64:274, 289
- risk of CHD
  - 71:8
- risk of COPD
  - 71:10
- risk ratios in
  - 64:31, 37, 231, 233
- tongue neoplasms in
  - 64:189, 202
- U.S. trends in number of
  - 64:26, 45
- see also* Smokers, cigar and pipe
- Smokers, cigar and pipe
  - causes of death in
    - 64:107
  - expected death rate in
    - 64:107
  - gastric neoplasm mortality in
    - 64:288
  - gastric ulcer in
    - 64:113
  - incidence of atypical nuclei in larynx
    - 69:59
  - incidence of coronary heart disease
    - 69:21, 24
  - incidence of gingivitis
    - 69:86
  - incidence of stomatitis nicotina
    - 69:87
  - liver cirrhosis in
    - 64:113
  - lung neoplasms in
    - 64:113
  - mortality ratios in
    - 64:107
  - observed deaths in
    - 64:107
  - oral neoplasms in
    - 64:113
  - thickness of vocal cords
    - 69:60
- see also* Smokers, cigar; Smokers, pipe
- Smokers, cigarette
  - air pollution effects on
    - 64:194, 195, 276, 295-298, 301, 302
  - arterial occlusions in
    - 71:73
  - atherosclerosis in aortic and coronary arteries
    - 71:52-56
  - atypical nuclei in male esophageal epithelium
    - 71:379-380
  - bladder neoplasms in
    - 71:293-295
  - bladder neoplasms mortality in
    - 64:32, 37, 219, 234
  - bronchitis in
    - 64:102, 103, 301
  - cell rows and atypical cells in vocal cords of
    - 71:280, 359-360
  - cessation of smoking, effects on COPD morbidity
    - 71:146, 197, 199, 203-204
  - cessation of smoking, lowers lung neoplasm rate in
    - 71:11
  - changes in ventilatory function and pulmonary histology
    - 71:175
  - comparative risk for lung neoplasms
    - 71:237
  - coronary diseases in
    - 64:322
  - coronary diseases in, AHA pooling project
    - 71:28, 30, 39
  - coronary diseases risk by
    - 71:8, 23-25
  - coronary mortality in
    - 64:324
  - decline in, British physicians
    - 71:48
  - development of altered ventilatory function in young
    - 71:10
  - development of esophageal neoplasms
    - 71:12, 293
  - development of laryngeal neoplasms
    - 71:12
  - development of oral neoplasms
    - 71:12
  - development of second primary oral neoplasms in continuing
    - 71:287
  - effect of filters on emphysema development
    - 71:162
  - effect on cardiovascular system
    - 71:56-58, 107-118
  - effects of inhalation on bronchial reactivity
    - 71:164
  - effects on uterine activity in gravidic women
    - 71:408
  - emphysema in
    - 64:277-294
  - emphysema mortality in
    - 64:102, 103
  - epithelial changes in
    - 64:170, 173, 189
  - esophageal neoplasms in
    - 64:102, 103, 188, 212, 213
  - esophageal neoplasms, mortality ratios in
    - 71:290-291

excess mortality in  
     64:108  
 expected mortality in  
     64:108  
 forced expiratory volume in  
     64:291  
 histology and smoking relationship of  
     lung neoplasms in  
         71:246-249  
 hypertension in  
     64:325  
 infant birth weight  
     71:397-399  
 inhalation effects on human pulmonary  
     function  
         71:163, 166-169  
 inhalation patterns in  
     64:159  
 kidney neoplasms in  
     64:102; 71:294-196  
 laryngeal neoplasm induction in  
     71:354-357  
 laryngeal neoplasm mortality in  
     64:32, 188, 205, 212, 234  
 lung neoplasms, etiology  
     71:239  
 lung neoplasms in  
     64:31, 37, 149-196, 229-233  
 lung neoplasms, mortality in  
     71:240-243-244  
 mortality from cerebrovascular disease  
     71:67-70  
 mortality from neoplasms, by site  
     64:149  
 mortality rates affected by sex  
     71:3  
 mortality rates in  
     64:35, 102, 106, 108, 109, 110, 115,  
     162, 194, 3  
 mortality ratios  
     64:90, 93, 102, 103  
 mortality ratios from COPD  
     71:142-144  
 mortality ratios from pancreatic neo-  
     plasms in  
         71:298  
 mortality ratios from peptic ulcers in  
     71:424  
 nonrespondents, mortality in  
     64:115  
 oral neoplasms, mortality in  
     64:102, 103, 131, 132, 196-205, 233  
 otolaryngological symptoms in  
     64:275  
 peptic ulcer  
     71:427  
 peptic ulcer in, smoke effects on antacid  
     therapy  
         71:423  
 percent of population as  
     64:26  
 percent of women of childbearing age  
     71:389  
 pharyngeal neoplasms in  
     64:103, 202  
 possible processes for increased mor-  
     tality in  
         71:4-5  
 postoperative pulmonary complications  
     in  
         71:174, 230  
 pulmonary surfactant activity in  
     71:172, 225  
 relationship in coronary and lower limb  
     arteriosclerosis  
         71:72  
 relationship of asbestos in lung neoplasm  
     mortality  
         71:257  
 relationship to infectious respiratory dis-  
     eases  
         71:172, 226-229  
 relationship to laryngeal neoplasm devel-  
     opment in  
         71:281  
 relationship to lip or oral cavity neo-  
     plasms  
         71:361-370  
 relationship to lung neoplasms  
         71:275, 276  
 relationship with bladder neoplasms in  
     men  
         71:299  
 relationship with dust on COPD develop-  
     ment  
         71:153  
 risk gradients in, from bladder neoplasms  
     64:223  
 risk gradients in, from esophageal neo-  
     plasms  
         64:234  
 risk gradients in, from laryngeal neo-  
     plasms  
         64:37, 211, 234  
 risk gradients in, from lung neoplasms  
     64:31, 37, 184, 185, 230  
 risk of COPD in  
     71:140  
 stomach ulcers in  
     64:103  
 survey by age and sex  
     71:6  
 survey of U.S.  
     71:6  
*see also* Smokers  
 Smokers, pipe  
     amblyopia in  
         64:39, 341, 342  
     amount smoked, in mortality ratios  
         64:86, 87  
     atypical nuclei in male esophageal epi-  
         thelium  
             71:379  
     bladder neoplasms in  
         64:219, 222, 223, 235; 71:293-294  
     body weight in  
         64:384  
     carboxyhemoglobin levels in  
         72:21  
     cell rows and atypical cells in vocal cords  
         of  
             71:280, 359-360  
     COPD morbidity in  
         71:146, 197-198, 201-205  
     coronary mortality in  
         64:323

development of chronic bronchopulmonary disease  
     71:10  
 development of esophageal neoplasms  
     71:13, 293  
 development of lung neoplasms  
     71:11  
 development of oral neoplasms  
     71:12  
 duodenal ulcers in  
     64:37  
 epithelial changes in  
     64:170, 173, 189  
 esophageal neoplasms in  
     64:37, 212, 217, 218, 234  
 esophageal neoplasms, mortality ratios  
     71:290  
 extroversion in  
     64:366  
 fibrosis in  
     64:274  
 forced expiratory volume in  
     64:291  
 gastric ulcers in  
     64:37, 337  
 gingival neoplasms in  
     64:202  
 inhalation by  
     64:92, 188  
 kidney neoplasms in  
     71:294-295  
 lack of risk in CVD  
     71:67  
 laryngeal neoplasms in  
     64:37, 192, 209, 211, 212  
 laryngeal neoplasms, induction  
     71:12, 354-357  
 lip neoplasms in  
     64:32, 37, 188, 197, 204  
 lung neoplasms in  
     64:31, 37, 196, 233  
 lung neoplasms, incidence in Norway  
     71:244  
 lung neoplasms, incidence in rural Switzerland  
     71:244  
 lung neoplasms, mortality in  
     71:324-327  
 morphology of  
     64:385, 386  
 mortality rates  
     64:30, 36, 74, 194, 202, 222, 223  
 mortality rates from COPD  
     71:142-143, 145  
 mortality ratios  
     64:90, 91, 162  
 mortality ratios from pancreatic neoplasms  
     71:298  
 mortality ratios from peptic ulcer  
     71:424  
 myocardial arteriole wall thickness in  
     72:19  
 myocardial infarction in  
     71:32, 38-39  
 neoplasm location in  
     64:197  
 oral changes in  
     64:302  
 oral neoplasms and  
     64:37, 150, 189, 192, 202; 72:67  
 peptic ulcer in  
     71:427  
 pharyngeal neoplasms in  
     64:202  
 psychosomatic disorders in  
     64:367  
 relationship to infectious respiratory diseases  
     71:227  
 relationship to laryngeal neoplasm development  
     71:281  
 relationship to lip neoplasms  
     71:289  
 relationship to oral cavity neoplasms  
     71:361-364, 367  
 relative risk in esophageal neoplasm development  
     72:68  
 relative risk in laryngeal neoplasm development  
     71:67  
 relative risk in lung neoplasm development  
     71:276; 73:67, 68  
 respiratory diseases in  
     64:289, 299  
 risk of CHD  
     71:8  
 risk ratios in, from neoplasms  
     64:31, 37, 196, 209, 211, 231, 233, 235  
 tongue neoplasms  
     64:188, 189, 202  
*see also* Smokers, cigar and pipe  
*Smokers vs. ex-smokers*  
 atypical nuclei in larynx  
     69:59  
 coronary disease mortality rates, for men by age  
     67:49  
 coronary disease mortality rates, for men, by years stopped smoking  
     67:49; 69:15  
 coronary disease mortality rates, for men, compared to nonsmokers  
     69:15  
 coronary disease mortality rates for men, compared to nonsmokers  
     69:15  
 lung neoplasm mortality rates  
     67:34, 137, 139  
 morbidity rates  
     67:15  
 mortality rates  
     67:9, 15  
 peptic ulcer mortality rates by age  
     67:181  
 peptic ulcer mortality ratios by age  
     67:181  
 stroke mortality for men, compared to nonsmokers  
     69:15

thickness of vocal cords  
     69:60  
 Smokers vs. nonsmokers  
     abortions, still births, and neonatal death  
         71:390, 405-406  
     acute diseases in  
         67:22  
     o-aminophenols in urine of  
         69:64  
     angina pectoris morbidity ratios  
         67:59  
     aortic aneurysm mortality  
         69:16  
     arteriosclerosis  
         67:22; 72:19  
     arteriosclerosis, mortality rates  
         67:26  
     attitudes  
         67:190-191  
     atypical nuclei in larynx  
         69:59  
     bladder neoplasms in  
         71:293-295, 381-384  
     bladder neoplasms, mortality rates, by  
         age  
             67:154, 155  
     blood cholesterol levels, twin studies  
         67:55  
     blood factors of mothers and infants  
         69:80  
     body constitution  
         67:99  
     breathlessness in  
         67:29, 286  
     bronchitis mortality rates  
         67:8, 29, 90-92  
     carboxyhemoglobin levels  
         67:100; 72:21-23  
     cardiopulmonary function, in young  
         male  
             67:100  
     cell rows and atypical cells in vocal cords  
         of  
             71:280, 359-360  
     cerebrovascular diseases  
         72:25  
     cerebrovascular diseases mortality rates  
         67:66; 71:67-70  
     cerebrovascular diseases mortality ratios  
         67:66  
     chronic diseases in  
         67:22  
     coronary disease incidence  
         69:18, 20-22  
     coronary disease incidence and behavior  
         type  
             69:24  
     coronary disease incidence rates, by age  
         67:54, 65  
     coronary disease morbidity ratios  
         67:59; 71:24  
     coronary disease morbidity ratios, and  
         blood pressure status  
             67:55  
     coronary disease morbidity ratios, and  
         lung function  
             67:56

    coronary disease morbidity ratios, by age  
         67:54  
     coronary disease morbidity ratios, by  
         blood cholesterol levels  
         67:55  
     coronary disease morbidity ratios, by  
         personality characteristics  
         67:57  
     coronary disease morbidity ratios, by  
         sociocultural mobility status  
         67:57  
     coronary disease mortality  
         67:47; 71:21-22, 24, 26-29  
     coronary disease mortality, by age  
         67:50; 69:13  
     coronary disease mortality, by amount  
         smoked  
             67:51; 69:13  
     coronary disease mortality, by sex  
         67:50; 69:13; 71:28-31  
     coronary disease mortality, by smoking  
         history  
             67:51  
     coronary disease mortality, for men  
         67:27  
     coronary disease mortality, for women  
         67:28  
     coronary disease mortality, in Swedish  
         twins  
             71:51  
     coronary disease mortality ratios  
         67:8  
     coronary disease mortality ratios, by age  
         67:49, 52; 69:13  
     coronary disease mortality ratios, by  
         amount smoked  
         67:47-49; 69:13  
     coronary disease mortality ratios, by  
         blood pressure status  
         67:52  
     coronary disease mortality ratios, by sex  
         67:49; 69:13  
     cough in  
         67:29  
     Curschmann's spirals in sputum of  
         69:39-40  
     development of COPD in  
         71:141, 145, 195-205  
     differences in emphysema types in  
         71:154, 156  
     digestive tract neoplasm mortality rates  
         67:147  
     emphysema mortality rates  
         67:8  
     emphysema mortality ratios  
         67:90-92  
     esophageal epithelial cells with atypical  
         nuclei in  
             71:292  
     esophageal neoplasm mortality rates, for  
         men by age  
             67:150  
     esophageal neoplasm mortality ratios  
         67:35, 150-151; 71:290-291  
     excretion of tryptophan metabolites in  
         71:297  
     frequency of esophageal neoplasms in  
         71:296

frequency of kidney neoplasms in  
     71:238  
 frequency of mouth and pharyngeal neoplasms in  
     71:238  
 frequency of urinary bladder neoplasms in  
     71:238  
 group characteristics in lung neoplasms and smoking in  
     71:240, 244, 329-333  
 3-hydroxyanthranilic acid urinary excretion in  
     67:156  
 3-hydroxykynurenine urinary excretion in  
     67:156  
 incidence of edentulism  
     69:87  
 incidence of gingivitis  
     69:86  
 incidence of periodontal disease  
     69:85-86  
 incidence of preeclampsia among pregnant women  
     69:79  
 laryngeal neoplasm mortality rates  
     67:148; 71:237-238  
 laryngeal neoplasm mortality ratios  
     67:35; 71:278-279  
 laryngeal neoplasms in, relationship to tobacco use  
     71:354-357  
 lung fibrosis development in  
     71:161  
 lung neoplasm mortality in uranium miners  
     71:256  
 lung neoplasm mortality rates  
     67:8, 34, 47  
 lung neoplasm mortality rates, by age  
     67:132-138, 140  
 lung neoplasm mortality rates, by sex  
     67:136, 140  
 lung neoplasm mortality rates, for men by age  
     67:131-132, 134-135, 137-140  
 lung neoplasm mortality rates, for men by amount smoked  
     67:134-135, 137-140  
 lung neoplasm mortality rates, for men by smoking characteristics  
     67:134-135, 139  
 lung neoplasm mortality rates, for men by smoking history  
     67:134-135, 137-140  
 lung neoplasm mortality rates, for women  
     71:240-243  
 lung neoplasm mortality ratios, by age  
     67:134-140  
 lung neoplasm mortality ratios, by sex  
     67:136, 140  
 lung neoplasm mortality ratios, by smoking classification  
     67:139  
 lung neoplasm mortality ratios, for men by age  
     67:134-135, 137-140  
 lung neoplasm mortality ratios, for men by amount smoked  
     67:134-135, 137-140  
 lung neoplasm mortality ratios, for men by smoking characteristics  
     67:134-135  
 lung neoplasm mortality ratios, for men by smoking history  
     67:134-135, 137, 139  
 lung neoplasm mortality ratios, for women  
     67:34, 136  
 lung neoplasm occurrence in asbestos workers  
     67:143  
 lung neoplasm occurrence in uranium workers  
     67:143  
 N-methylnicotinamide urinary excretion  
     67:156  
 morbidity rates, in United States  
     67:3, 5  
 mortality rates  
     71:3  
 mortality rates, by age  
     67:79-10  
 mortality rates, by occupation  
     67:11  
 mortality rates, for Canadian pensioners  
     67:10  
 mortality rates, for men by age  
     67:12-13  
 mortality rates, for U.S. veterans by age  
     67:12-13  
 mortality rates, for women by age  
     67:12-13, 21  
 mortality ratios, by age and sex  
     67:12-13  
 mortality ratios, for U.S. veterans by age  
     67:12-13  
 mortality ratios from pancreatic neoplasms in  
     71:298  
 mortality ratios, in United States  
     67:8  
 mortality ratios of COPD in  
     71:142-144  
 mouth neoplasm mortality rates  
     67:146  
 mouth neoplasm mortality ratios  
     67:35, 146  
 mucous gland abnormalities in  
     74:97  
 myocardial infarction morbidity ratios  
     67:59  
 myocardial infarction morbidity ratios, by physical activity levels  
     67:56  
 myocardial infarction relationships to physical activity  
     71:44  
 oral diseases and  
     72:6

pancreatic neoplasm mortality rates, by age  
 67:158-159  
 pancreatic neoplasm mortality rates, by amount smoked  
 67:159  
 pancreatic neoplasm mortality rates, by sex  
 67:158-159  
 pancreatic neoplasm mortality rates, by smoking classification  
 67:159  
 paralysis agitans mortality rates  
 67:8  
 pathological and cytological changes in respiratory tract of  
 71:258-263  
 peptic ulcer in, correlated amounts of tobacco use  
 71:427-428  
 peptic ulcer morbidity rates, by sex  
 67:182  
 peptic ulcer mortality rates, for men, by age  
 67:181  
 peptic ulcer mortality ratios, for men, by age  
 67:181  
 pharyngeal neoplasm mortality rates  
 67:146  
 pharyngeal neoplasm mortality ratios  
 67:35, 146  
 postoperative hypoxemia in  
 71:174-230  
 postoperative pulmonary complications in  
 71:174-175, 230  
 postural hypoxemia mechanism in symptomatic  
 71:147  
 prevalence of neoplasms, by type of tumor, sex and  
 69:56  
 pulmonary alveolar phagocytosis in  
 71:165  
 relation between CHD and serum cholesterol level  
 71:43  
 relationship to infectious respiratory disease  
 71:172, 226-229  
 respiratory symptoms  
 72:40  
 respiratory symptoms by age  
 67:29, 100  
 respiratory symptoms by occupation  
 67:97  
 respiratory tract neoplasm mortality rates  
 67:147  
 serum lipids in  
 71:41, 98-102  
 small airways abnormalities in  
 74:97, 98  
 stomach neoplasm mortality rates  
 67:157-158  
 stroke mortality, by age  
 69:13  
 stroke mortality, by amount smoked  
 69:13  
 stroke mortality, by sex  
 69:13  
 stroke mortality, compared to ex-smokers  
 69:15  
 stroke mortality ratios, by age  
 69:13  
 stroke mortality ratios, by amount smoked  
 69:13  
 stroke mortality ratios, by sex  
 69:13  
 surfactant activity in lungs of  
 71:172, 225  
 thickness of myocardial arteriole walls  
 72:19  
 thickness of vocal cords  
 69:60  
 tracheal neoplasm mortality rates  
 67:147  
 type of lung neoplasms in male and female  
 71:250  
 urinary excretion of tryptophan metabolites  
 69:64  
 urinary tract neoplasm mortality rates, by age  
 67:154  
*see also* Smokers vs. nonsmokers, cigar; Smokers vs. nonsmokers, pipe  
 Smokers vs. nonsmokers, cigar  
 esophageal neoplasm mortality ratios  
 67:35-36  
 laryngeal neoplasm mortality ratios  
 67:35  
 mortality rates  
 67:8  
 and mouth neoplasm mortality ratios  
 67:35  
 and pharyngeal neoplasm mortality ratios  
 67:35  
 Smokers vs. nonsmokers, pipe  
 esophageal neoplasm mortality ratios  
 67:35  
 laryngeal neoplasm mortality ratios  
 67:35, 149  
 mortality rates  
 67:8  
 mortality rates for Canadian pensioners  
 67:10  
 mouth neoplasm mortality rates  
 67:35  
 pharyngeal neoplasm mortality ratios  
 67:35  
 Smoke streams  
 aluminum in  
 64:55, 61, 62  
 arsenic in  
 64:55  
 benzo(a) pyrene content  
 72:123  
 beryllium in  
 64:55  
 chromium in  
 64:55

- CO levels in mainstream cigar smoke
  - 75:90
- constituents of tobacco smoke
  - 75:88-98
- definition of
  - 64:50
- effect on nonsmokers
  - 72:122, 123
- Guthion in
  - 64:62
- nickel in
  - 64:55
- potassium in
  - 64:55
- Sevin in
  - 64:62
- sodium in
  - 64:55
- summary of previous findings
  - 75:87, 88
- tar and nicotine content
  - 72:123
- Smoke, tobacco
  - 64:26, 33, 34, 50-62, 69-75, 142-146, 167, 168, 263-267
  - acenaphthene in
    - 64:55
  - air cured and tumorigenicity
    - 68:91
  - as air pollutant
    - 72:7, 121, 122
  - alkylbenzene in
    - 64:55
  - allergic and irritative components, effect
    - on nonsmokers
    - 72:2, 128, 129
  - antigenic properties
    - 72:104
  - aromatic hydrocarbons in
    - 64:55; 67:127; 69:61
  - arsenic in
    - 64:55, 61
  - benz(a)anthracene in
    - 67:127
  - benzene in
    - 64:55
  - benzo(b)fluoranthene in
    - 67:127
  - benzo(j)fluoranthene in
    - 67:127
  - benzo(k)fluoranthene in
    - 67:127
  - benzo(a)pyrene in
    - 67:127
  - benzo(e)pyrene in
    - 67:127
  - beryllium in
    - 64:55
  - bladder carcinogens in
    - 69:64
  - and bronchogenic carcinoma
    - 67:129-130
  - carcinogenic heterocyclics in
    - 64:54
  - carcinogenic hydrocarbons in
    - 64:55
  - carcinogenicity
    - 64:143, 145; 68:90, 91; 69:62
  - chromium as
    - 64:55
  - chronic toxicity of
    - 64:73
  - chrysene in
    - 67:127
  - clearance mechanism for
    - 64:267, 269
  - cocarcinogens in
    - 69:61
  - composition of
    - 64:50-62, 263, 264
  - constituents of
    - 64:51
  - constituents of, and bladder neoplasm carcinogenesis
    - 67:156
  - constituents of, effect on bronchial mu-  
cosa
    - 67:144-145
  - constituents of, lung neoplasms induced  
by
    - 67:144
  - cyanide in, and vitamin B-12 deficiency,  
in tobacco amblyopia
    - 67:40
  - deposition of
    - 64:263-267
  - dibenz(a,j)acridine in
    - 67:127
  - effect during pregnancy in laboratory  
animals
    - 73:114, 115
  - effect of constituents on passive smokers
    - 75:88-98
  - effect on air pollution in aircraft
    - 73:45
  - effect on bronchial epithelium
    - 67:129
  - effect on macrophages
    - 72:47
  - effect on mitochondrial function, in rat  
liver
    - 74:104
  - effect on nonsmokers, in aircraft
    - 73:45
  - effect on stillbirth rate in laboratory  
animals
    - 73:125
  - and epidermoid carcinoma
    - 67:129-130
  - exposure
    - 64:272
  - filtration of, effect on bronchoconstric-  
tor response in smokers
    - 72:45
  - heterocyclic nitrogen compounds in
    - 67:127
  - indeno(1,2,3-c,d) pyrene in
    - 67:127
  - irritants in
    - 72:109, 110
  - leukoplakia from
    - 64:233
  - liver effect of
    - 64:342
  - and lung neoplasms in animals
    - 68:93



- nicotine content of
  - 68:91
- nicotine-N-oxides in
  - 69:62
- nitrites in
  - 67:128
- N-nitrosamines in
  - 67:127
- organ toxicity of
  - 64:73
- papilloma formation in tracheobronchial mucosa
  - 67:129-130
- pH of, effect of leaf constituents
  - 73:224
- polonium-210 content, and carcinogenesis
  - 68:92
- polycyclic aromatic compounds
  - 64:26, 144
- potassium
  - 64:55
- potential source of N-nitrosamines
  - 68:91
- pyrolytic temperature effect in
  - 64:50
- retention of
  - 64:263-267
- summary of previous findings on relationship to passive smoking
  - 75:87, 88
- summary of recent findings
  - 75:108
- systemic toxicity of
  - 64:73
- tar content of
  - 68:91
- in tobacco amblyopia etiology
  - 67:40
- toluene
  - 64:55
- toxicity of
  - 64:73
- tumorigenic activity
  - 68:90, 91; 73:210-214
- tumor-promoting agents in, and neoplasm pathogenesis
  - 67:35
- and vitamin B deficiency in tobacco amblyopia
  - 67:40
- see also* Smoke, cigar; Smoke, cigarette; Smoke, pipe
- Smoking
  - and absenteeism
    - 67:19
  - and adenocarcinoma
    - 67:140-143
  - and air pollution
    - 64:295-298
  - and air pollution, effect on pulmonary function and COPD prevalence
    - 74:82, 83
  - and alcohol consumption, in esophageal neoplasm formation
    - 67:152
  - and alveolar bone loss
    - 69:85-87
  - and alveolar cell carcinoma
    - 67:142
  - and angina pectoris
    - 69:18
  - and anoxia
    - 67:183
  - and aortic aneurysm
    - 67:183
  - and arrhythmia
    - 69:4
  - and arteriosclerosis
    - 67:28; 69:4, 5
  - and asbestos exposure, as factors in lung neoplasm development
    - 74:41-43
  - association with other risk factors in CHD
    - 68:21; 74:6, 7, 17
  - and asthma
    - 67:29
  - and atherogenesis
    - 67:66
  - and basal cell hyperplasia
    - 67:30
  - and bed days
    - 67:20-22
  - and behavior type
    - 69:20, 24
  - and bladder neoplasms
    - 67:33, 36; 69:60; 72:68, 72-74
  - and bladder neoplasms in men
    - 67:153
  - and bronchitis
    - 69:4; 74:79
  - and bronchitis morbidity
    - 67:6, 94, 99
  - and bronchitis mortality
    - 67:3, 29, 90-92
  - in bronchitis pathogenesis
    - 67:29-31, 96, 108; 69:37-40
  - and carboxyhemoglobin levels in smokers
    - 67:183
  - and cardiovascular diseases
    - 67:3, 25-28, 47-69; 69:3-5
  - as cause of fires
    - 67:187-188
  - as cause of traffic accidents
    - 67:187-188
  - and cerebrovascular diseases
    - 67:27, 66
  - and cerebrovascular diseases by age
    - 67:68
  - and cerebrovascular thrombosis
    - 67:27, 68
  - cigarette sales and CHD mortality rate
    - 68:16
  - and coffee drinking, in myocardial infarction etiology
    - 74:8
  - and COPD etiology
    - 73:35, 36
  - and coronary disease
    - 69:3-5, 20
  - and coronary disease, age as factor
    - 74:6
  - in coronary disease etiology
    - 67:26, 54